Malignant Mesothelioma

Treatment for malignant mesothelioma granted orphan status in Australia

Published in Cancer Weekly, April 26th, 2005

Alfacell Corporation (ACEL) announced that the Therapeutic Goods Administration (TGA) in Australia has granted ONCONASE (ranpirnase) orphan drug status for the indication of malignant mesothelioma (MM).

ONCONASE is also designated as an orphan drug for MM in Europe.

The TGA defines orphan drug products as "drugs, vaccines or in vivo diagnostic agents which physicians use to treat, prevent or diagnose rare diseases." The TGA's Orphan Drug Program encourages sponsors to market orphan drugs in Australia by reducing costs through waiving fees. In addition, orphan drug status in Australia confers priority evaluation for ONCONASE ahead of other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry